Abstract
The immunohistochemical classification of Human Epidermal Growth Factor Receptor 2 (HER2) expression is optimized to detect HER2-amplified breast cancer (BC). However, novel HER2 targeting agents are also effective for BCs with low levels of HER2 expression. This raises the question whether the current guidelines for HER2-testing are sufficiently reproducible to identify HER2 low BC. The aim of this multicenter international study was to assess the interobserver agreement of HER2 low scoring according to the current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
